U.S. Food and Drug Administration (FDA) Workshop: Clinical Trial Design for Non-Muscle Invasive Bladder Cancer (NMIBC)

November 18 (9 am - 1 pm ET) and November 19 (9 am - 12 pm ET)

AGENDA Day 1: November 18, 2021 (9:00 am – 1:00 pm ET)			
BCG Shortage, Trial Design for BCG-Naïve Patients, Risk Stratification and Definition of Disease States, Bladder-Intact and High-Grade Event-Free Survival			
Welcome and Introduction	Elaine Chang	09:00-09:15	
Session 1			
BCG Shortage: The Practice Environment (15 mins)	Seth Lerner	09:15-09:30	
BCG Shortage: Strains of BCG (15 mins)	Robert Svatek	09:30-09:45	
Panel Discussion: BCG Shortage (35 mins)	Moderator: Chana Weinstock Panelists: Seth Lerner, Neal Shore, Robert Svatek, Max Kates, Peter Bross, Karen Sachse	09:45-10:20	
Break (10 mins)		10:20-10:30	
Session 2			
BCG-Naïve Setting (15 mins)	Noah Hahn	10:30-10:45	
Panel Discussion: BCG-Naïve Setting (35 mins)	Moderator: Adnan Jaigirdar Panelists: Jamie Brewer, Seth Lerner, Michael O'Donnell, Noah Hahn, Gary Steinberg	10:45-11:20	
Break (10 mins)		11:20-11:30	
Session 3			
Risk Stratification, BCG-Unresponsive and Definitions of Disease States (15 mins)	Ashish Kamat	11:30-11:45	
Cystectomy: Clinical Context (10 mins)	Maria Ribal	11:45-11:55	
Cystectomy-Free Survival (15 mins)	Paul Kluetz	11:55-12:10	
Panel Discussion: BCG- Unresponsive and Definition of Disease States, Cystectomy-Free Survival (45 mins)	Moderator: Charles Viviano Panelists: Paul Kluetz, Ashish Kamat, Matt Galsky, Rick Oliver, Erik Bloomquist, Maria Ribal	12:10-12:55	
Wrap-up of Day 1 (5 mins)	Jaleh Fallah	12:55-1:00	

U.S. Food and Drug Administration (FDA) Workshop: Clinical Trial Design for Non-Muscle Invasive Bladder Cancer (NMIBC)

November 18 (9 am - 1 pm ET) and November 19 (9 am - 12 pm ET)

AGENDA Day 2: November 19, 2021 (9:00 am-12:00 pm ET)			
Carcinoma In Situ (CIS), Papillary, and Patient-Focused Drug Development			
Welcome and Recap Day 1 (10 mins)	Chana Weinstock	09:00-09:10	
Session 4			
What is Success for CIS? (20 mins)	Sundeep Agrawal Peter Black Hikmat Al-Ahmadie	09:10-09:30	
Panel Discussion (CIS) (30 mins)	Moderator: Jaleh Fallah Panelists: Sundeep Agrawal, Peter Black, Hikmat Al-Ahmadie, Kamal Pohar	09:30-10:00	
Break		10:00-10:10	
Session 5			
Pathways for Papillary Ta/T1 Disease (25 mins)	Colin Dinney Zhou Feng	10:10-10:35	
Panel Discussion: Papillary (30 mins)	Moderator: Noah Hahn Panelists: Zhou Feng, Seth Lerner, Sima Porten, Colin Dinney, Tracy Downs	10:35-11:05	
Break		11:05-11:10	
Session 6			
Patient-Focused Drug Development: Capturing High-Quality Patient Experience Data (15 mins)	Angela Smith	11:10-11:25	
Panel Discussion: Patient-Focused Drug Development and Patient-Reported Outcomes (30 mins)	Moderator: Neeraj Agarwal Panelists: Angela Smith, Sarah Psutka, Rick Bangs, Vishal Bhatnagar, Ken Brothers	11:25-11:55	
Wrap-up and Next Steps	Elaine Chang	11:55-12:00	